TMR Management with FreshFoss under Warm Weather Conditions
Understanding TMR stability and intake: why warm weather challenges are back in focus for dairy farms.
EU reaches landmark Omnibus VI deal: Industry welcomes streamlined substance statutes
The European Council and European Parliament have reached a provisional interinstitutional agreement on the Omnibus VI package, a legal overhaul of cosmetic regulations in Europe presented by the European Commission (EC). The Council and Parliament are pushing to eliminate cosmetics containing carcinogenic, mutagenic, and reprotoxic substances (CMR) more quickly than the EC had proposed.
AMSilk Appoints Former Evolva CEO Christian Wichert as New Chief Executive
German biotech materials company AMSilk has named Christian Wichert as its new Chief Executive Officer. He succeeds Ulrich Scherbel, who will take on the role of Chief Operating Officer for AMSilk’s Premium Filaments division.
Solar Foods wins $89.2m backing for ‘protein from air’ factory, but final investment decision still pending
Finnish startup Solar Foods has just secured €77.8 million ($89.2 million) in grants and loans from Business Finland tow…
Here’s Why Regenerative Farming Is a Risk Management Story, Not an ESG Story
By Artem Milinchuk, Founder & Head of Strategy, FarmTogether, a farmland investment managerA new documentary is making the rounds. Groundswell — the third chapter in the trilogy
that began with Kiss the Ground — premiered at Cannes in May and launched on Amazon
Prime on World Environment Day (this past Friday, June 5th). Narrated by Demi Moore and
Woody Harrelson, I found it sweeping, cinematic, and genuinely compelling. It covers five
continents and makes a case for regenerative agriculture as a solution to soil loss, biodiversity
collapse, and climate change.
Jazz Pharmaceuticals inks $4bn cancer collab with Peter Thiel’s biotech project AbCellera
The companies said the preclinical research collaboration, option and license agreement will discover and develop next-generation T-cell engaging (TCE) multispecific antibodies. Involving up to five drug candidates, this could be the largest such deal struck by Jazz, and will be based around AbCellera’s antibody discovery technology. The partnership will work on optimised development candidates for multiple gastrointestinal (GI) cancers and other solid tumours.
Tech alone won’t future-proof the food system, experts warn
Governments and businesses have more tools than ever for spotting vulnerabilities in the food system before they trigger…
创制突破、供应链重构、市场深耕—CPEW 2026 详细议程发布（最新）
农药行业正在经历一场深刻的洗礼——从"效率优先"到"韧性优先"，从"成本之争"到"规则之争"，从"跟随"到"创制"。
Univar strengthens botanical extract portfolio with American Distilling partnership
Univar Solutions has expanded its distribution partnership with American Distilling within its Ingredients + Specialties division.
F2G’s oral antifungal clears Phase III hurdle
Azole antifungals remain the mainstay of treatment for invasive aspergillosis, but they are not suitable for every patient. Resistance to azoles is an increasing clinical problem, while drug–drug interactions, liver toxicity and tolerability issues can limit their use in the severely immunocompromised patients most at risk of the infection. In these cases, physicians often turn to alternative antifungals, including liposomal amphotericin B such as Gilead’s AmBisome, despite its need for intravenous administration and its own toxicity burden.